Navigation Links
Alimera Sciences Closes $5 Million in Extended Series C Financing
Date:8/27/2009

ATLANTA, Aug. 27 /PRNewswire/ -- Alimera Sciences, Inc., today announced that it has closed a $5 million extension of its Series C financing which was originally completed in March 2008. In connection with this financing, the purchasers of the $5 million in Series C preferred stock received warrants for an additional $10 million in Series C preferred stock. The warrant holders will have up to 30 days from the delivery of Phase III top-line data for Iluvien(R) to elect to exercise the warrants. If the majority of the holders of warrants make such election, then all warrant holders will be required to exercise their warrants in full. Alimera expects to receive the Phase III top-line data for Iluvien in December of this year.

Iluvien is an investigative, extended release intravitreal insert that Alimera is developing for the treatment of diabetic macular edema (DME). Currently, nearly 24 million people, or 8 percent of the population, in the U.S. have diabetes. Over time, all diabetics are at risk of developing DME. Based on published data, Alimera estimates that there are as many as 300,000 new cases of DME each year and 1,000,000 people have DME. There are no ophthalmic drug therapies currently approved by the U.S. Food and Drug Administration for the treatment of this disease.

Each Iluvien insert is designed to provide a sustained therapeutic effect of up to 36 months, for the low dose of Iluvien, and up to 24 months, for the high dose of Iluvien. Iluvien is inserted into the patient's eye with a 25-gauge needle, which allows for a self-sealing wound. This insertion is very similar to an intravitreal injection, a procedure commonly employed by retinal specialists.

About Alimera Sciences Inc.

Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien(R), which is being developed for the treatment of diabetic macular edema, or DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Under one protocol, enrollment was completed in October 2007 in two Phase 3 pivotal trials for the use of Iluvien in the treatment of DME conducted across the U.S., Canada, Europe and India.

Alimera also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment strategy for ophthalmic diseases. Under this agreement, Alimera has acquired options to exclusive, worldwide licenses for two classes of nicotinamide adenine dinucleotide phosphate reduced form (NADPH) oxidase inhibitors, which Alimera is studying as potential treatments for conditions such as the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition known as geographic atrophy. Alimera has exercised its option to acquire a license with respect to one of these classes of NADPH oxidase inhibitors.


'/>"/>
SOURCE Alimera Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD
2. Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement
3. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
4. Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud"
5. PharmaTelevision Launches the First Daily News Show for the Life Sciences Industry
6. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
7. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
8. Advanced Life Sciences Announces Second Quarter 2009 Financial Results and Financial Outlook
9. BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels
10. Ingenuitys Technology Powers BD Cell Pathways Tool on New BD Biosciences Website
11. YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, ... Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February ... than 100 tables for its annual event, which will run from 3:00 p.m. ...
(Date:2/10/2016)... ... February 10, 2016 , ... Curoverse announced today that ... Arvados provides capabilities for managing and processing genomic and health data at petabyte ... institutions collecting and analyzing genomic data,” said Adam Berrey chief executive officer at ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... With a ... 2016 Wharton Health Care Business Conference will bring together over 500 top healthcare leaders ... an industry in transformation. The conference, organized by MBA students of the University of ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... on its free and validated Electronic Data Capture (EDC) system ClinCaptureand its new ... Clinical Trials West Coast 2016 Conference in San Mateo, California on February 10th ...
Breaking Biology Technology:
(Date:1/15/2016)... Rico , Jan. 15, 2016 Recent ... and small to find new ways to ensure data ... iOS and Android that ... on biometrics, transforming it into a hardware authorization token. ... users swipe their fingerprint on their KodeKey enabled device ...
(Date:1/13/2016)... 13, 2016 ... of the  "India Biometrics Authentication & ... (2015-2020)"  report to their offering.  ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the leading ... 10,000 retail locations, web and mobile, today announced ... million from existing investors. --> ... devoted to further innovate higi,s health platform – ... web portal – including expanding services and programs ...
Breaking Biology News(10 mins):